Home
|
Inbox
|
Search
|
View Abstract
Adherence to Different Types of Inhaled Treatment Using Self-Reporting Questionnaires TAI Questionnaire and MMAS-8 Scale: The LASSYC Study
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A4248 - Adherence to Different Types of Inhaled Treatment Using Self-Reporting Questionnaires TAI Questionnaire and MMAS-8 Scale: The LASSYC Study
Author Block: M. Montes de Oca1, A. Casas2, L. Ugalde Gamboa3, A. Menezes4, M. V. Lopez5, L. Ramirez6, A. Ramirez-Venegas7, L. Mendoza8, A. Lopez9, M. Miravitlles10; 1Pulmonology, Hospital Universitario de Caracas, Caracas, Venezuela, Bolivarian Republic of, 2Fundacion Neumologica Colombiana, Bogota, Colombia, 3Clínica Americana, San José, Costa Rica, 4Faculty of Medicine, Pelotas,RS, Brazil, 5Universidad de la República, Montevideo, Uruguay, 6AstraZeneca, Escazú, Costa Rica, 7Departamento de Investigacion en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias, Mexio City, Mexico, 8Hospital Clinico Universidad De Chile, Santiago, Chile, 9Hospital Nacional de Clínicas de Córdoba, Cordoba, Argentina, 10Pneumology, Hospital Vall d'Hebron, Barcelona, Spain.
Adherence to different types of inhaled treatment using self-reporting questionnaires (TAI questionnaire and MMAS-8 scale): The LASSYC Study
Maria Montes de Oca1, Alejandro Casas2; Ana Menezes3, Luis Ugalde4, Victorina López5, Larissa Ramirez6, Alejandra Ramírez-Venegas7, Laura Mendoza8; Ana López9, Marc Miravitlles10
1Universidad Central de Venezuela, Venezuela; 2Fundación Neumológica Colombiana, Colombia; 3Federal University of Pelotas, Brazil; 4Clínica Americana, San José, Costa Rica; 5 Universidad de la República, Uruguay; 6Astra Zeneca, Costa Rica; 7Instituto Nacional de Enfermedades Respiratorias, Mexico,
8Hospital Clínico Universidad de Chile, Chile; 9Hospital Nacional de Clínicas de Córdoba, Argentina; 10Department of Pneumology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Background: Poor adherence to inhaled therapies is common in COPD patients and associated with poor outcomes. Limited information exists regarding the adherence to different types of inhaled medication in stable COPD patients from Latin American region.
Objective: To determine the adherence to different inhaled therapies in COPD patients according to two self-reporting adherence questionnaires.
Methods: 795 COPD patients participated in an observational, cross-sectional multinational study. Adherence to inhaled therapy was assessed with the Test of Adherence to Inhalers (TAI) and the Morisky-Green (MMAS-8) questionnaires. The type of medication was assessed as short-acting β-agonists or muscarinic antagonists (SABA or SAMA only), long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, and other.
Results: Among participating patients, 59.6% were male, with age of 69.5±8.7 years, and FEV1% 50.0±18.6%. According to the TAI questionnaire treatment regimens with SA-BDs (poor adherence 52.4%, intermediate 23.8% and good 23.8%), and ICS monotherapy (poor adherence 44%, intermediate 26.6% and good 29.4%) showed the lowest adherence. Treatment with LA-BDs had better adherence: LABA (poor 9.8%, intermediate 27.5% and good 62.7%), LAMA (poor 17.7%, intermediate 15.6% and good 66.7%), LABA/LAMA (poor 6.7%, intermediate 26.7% and good 66.6%), ICS/LABA (poor 20.2%, intermediate 30.7% and good 49.1%), and ICS/LAMA/LABA (poor 13.1%, intermediate 26% and good 60%). Similar findings were found using the MMAS-8 scale.
Conclusion: Treatment regimens including the use of LA-BDs are associated with the highest adherence. There is also a better adherence to LAMA, LABA or LABA/LAMA treatments compared with ICS/LABA. Adherence to inhaled treatment is crucial for optimizing clinical outcomes in COPD, therefore greater efforts should be made for improving adherence in these patients.
Author Block: M. Montes de Oca1, A. Casas2, L. Ugalde Gamboa3, A. Menezes4, M. V. Lopez5, L. Ramirez6, A. Ramirez-Venegas7, L. Mendoza8, A. Lopez9, M. Miravitlles10; 1Pulmonology, Hospital Universitario de Caracas, Caracas, Venezuela, Bolivarian Republic of, 2Fundacion Neumologica Colombiana, Bogota, Colombia, 3Clínica Americana, San José, Costa Rica, 4Faculty of Medicine, Pelotas,RS, Brazil, 5Universidad de la República, Montevideo, Uruguay, 6AstraZeneca, Escazú, Costa Rica, 7Departamento de Investigacion en Tabaquismo y EPOC, Instituto Nacional de Enfermedades Respiratorias, Mexio City, Mexico, 8Hospital Clinico Universidad De Chile, Santiago, Chile, 9Hospital Nacional de Clínicas de Córdoba, Cordoba, Argentina, 10Pneumology, Hospital Vall d'Hebron, Barcelona, Spain.
Adherence to different types of inhaled treatment using self-reporting questionnaires (TAI questionnaire and MMAS-8 scale): The LASSYC Study
Maria Montes de Oca1, Alejandro Casas2; Ana Menezes3, Luis Ugalde4, Victorina López5, Larissa Ramirez6, Alejandra Ramírez-Venegas7, Laura Mendoza8; Ana López9, Marc Miravitlles10
1Universidad Central de Venezuela, Venezuela; 2Fundación Neumológica Colombiana, Colombia; 3Federal University of Pelotas, Brazil; 4Clínica Americana, San José, Costa Rica; 5 Universidad de la República, Uruguay; 6Astra Zeneca, Costa Rica; 7Instituto Nacional de Enfermedades Respiratorias, Mexico,
8Hospital Clínico Universidad de Chile, Chile; 9Hospital Nacional de Clínicas de Córdoba, Argentina; 10Department of Pneumology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Background: Poor adherence to inhaled therapies is common in COPD patients and associated with poor outcomes. Limited information exists regarding the adherence to different types of inhaled medication in stable COPD patients from Latin American region.
Objective: To determine the adherence to different inhaled therapies in COPD patients according to two self-reporting adherence questionnaires.
Methods: 795 COPD patients participated in an observational, cross-sectional multinational study. Adherence to inhaled therapy was assessed with the Test of Adherence to Inhalers (TAI) and the Morisky-Green (MMAS-8) questionnaires. The type of medication was assessed as short-acting β-agonists or muscarinic antagonists (SABA or SAMA only), long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, and other.
Results: Among participating patients, 59.6% were male, with age of 69.5±8.7 years, and FEV1% 50.0±18.6%. According to the TAI questionnaire treatment regimens with SA-BDs (poor adherence 52.4%, intermediate 23.8% and good 23.8%), and ICS monotherapy (poor adherence 44%, intermediate 26.6% and good 29.4%) showed the lowest adherence. Treatment with LA-BDs had better adherence: LABA (poor 9.8%, intermediate 27.5% and good 62.7%), LAMA (poor 17.7%, intermediate 15.6% and good 66.7%), LABA/LAMA (poor 6.7%, intermediate 26.7% and good 66.6%), ICS/LABA (poor 20.2%, intermediate 30.7% and good 49.1%), and ICS/LAMA/LABA (poor 13.1%, intermediate 26% and good 60%). Similar findings were found using the MMAS-8 scale.
Conclusion: Treatment regimens including the use of LA-BDs are associated with the highest adherence. There is also a better adherence to LAMA, LABA or LABA/LAMA treatments compared with ICS/LABA. Adherence to inhaled treatment is crucial for optimizing clinical outcomes in COPD, therefore greater efforts should be made for improving adherence in these patients.
|
Home
|
Inbox
|
Search
|